Mike Bock

Doctors looking for treatment options for bipolar mania would be wise to keep the following in mind: The presence of psychotic symptoms during the manic index episode, the number of past depressive episodes, and body mass index may be the best predictors of functional outcome at 6 months’ follow-up after a manic episode.

A team of researchers led by Dr. C. Mar Bonn<scaps>í</scaps>n of the University of Barcelona examined 169 patients with bipolar disorder I who suffered an acute manic episode and were treated clinically and followed up at 6 months. Bipolar severity was assessed using scores from the Functioning Assessment Short Test (FAST) scale. The researchers then used a multivariate analysis to identify six variables that best predicted functional outcome at 6-month follow-up after a manic episode. Only three of the variables were found to be statistically significant: the number of previous depressive episodes (P = .002), the presence of psychotic symptoms during the index manic episode (P = .031), and body mass index (P = .041).

“The effective prevention of depressive episodes may be crucial to prevent further disability. Moreover, early treatment of psychotic symptoms may be of importance to avoid the progression and further worsening of the manic episode. Finally, educating patients in healthy lifestyle, including exercise and eating habits, may also help to avoid long-term treatment side effects of those drugs often associated with weight increase or other comorbidities associated to weight gain,” wrote the investigators.

Read the full article here: Journal of Affective Disorders 2015;182:121-5 (http://dx.doi.org/10.1016/j.jad.2015.04.043).

[email protected]

Doctors looking for treatment options for bipolar mania would be wise to keep the following in mind: The presence of psychotic symptoms during the manic index episode, the number of past depressive episodes, and body mass index may be the best predictors of functional outcome at 6 months’ follow-up after a manic episode.

A team of researchers led by Dr. C. Mar Bonn<scaps>í</scaps>n of the University of Barcelona examined 169 patients with bipolar disorder I who suffered an acute manic episode and were treated clinically and followed up at 6 months. Bipolar severity was assessed using scores from the Functioning Assessment Short Test (FAST) scale. The researchers then used a multivariate analysis to identify six variables that best predicted functional outcome at 6-month follow-up after a manic episode. Only three of the variables were found to be statistically significant: the number of previous depressive episodes (P = .002), the presence of psychotic symptoms during the index manic episode (P = .031), and body mass index (P = .041).

“The effective prevention of depressive episodes may be crucial to prevent further disability. Moreover, early treatment of psychotic symptoms may be of importance to avoid the progression and further worsening of the manic episode. Finally, educating patients in healthy lifestyle, including exercise and eating habits, may also help to avoid long-term treatment side effects of those drugs often associated with weight increase or other comorbidities associated to weight gain,” wrote the investigators.

Read the full article here: Journal of Affective Disorders 2015;182:121-5 (http://dx.doi.org/10.1016/j.jad.2015.04.043).

[email protected]

Doctors looking for treatment options for bipolar mania would be wise to keep the following in mind: The presence of psychotic symptoms during the manic index episode, the number of past depressive episodes, and body mass index may be the best predictors of functional outcome at 6 months’ follow-up after a manic episode.

A team of researchers led by Dr. C. Mar Bonn<scaps>í</scaps>n of the University of Barcelona examined 169 patients with bipolar disorder I who suffered an acute manic episode and were treated clinically and followed up at 6 months. Bipolar severity was assessed using scores from the Functioning Assessment Short Test (FAST) scale. The researchers then used a multivariate analysis to identify six variables that best predicted functional outcome at 6-month follow-up after a manic episode. Only three of the variables were found to be statistically significant: the number of previous depressive episodes (P = .002), the presence of psychotic symptoms during the index manic episode (P = .031), and body mass index (P = .041).

“The effective prevention of depressive episodes may be crucial to prevent further disability. Moreover, early treatment of psychotic symptoms may be of importance to avoid the progression and further worsening of the manic episode. Finally, educating patients in healthy lifestyle, including exercise and eating habits, may also help to avoid long-term treatment side effects of those drugs often associated with weight increase or other comorbidities associated to weight gain,” wrote the investigators.

Read the full article here: Journal of Affective Disorders 2015;182:121-5 (http://dx.doi.org/10.1016/j.jad.2015.04.043).

[email protected]

Thyroid dysfunction was associated with an increased risk of mortality in patients with heart failure due to idiopathic dilated cardiomyopathy (IDCM), according to research reported in the Journal of Clinical Endocrinology and Metabolism.

Lead author Wenyao Wang of the Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, and associates gathered data from 458 consecutive patients with IDCM who were admitted to the National Center of Cardiovascular diseases in Beijing, and then evaluated their risk of mortality based on levels of free T₃ and TSH and the whole thyroid function profile.

Hypothyroidism was the strongest predictor of mortality (hazard ratio, 4.189; 95% confidence interval, 2.118-8.283), followed by low-T₃ syndrome (HR, 3.147; 95% CI, 1.558-6.355) and subclinical hypothyroidism (HR, 2.869; 95% CI, 1.817-4.532); subclinical hyperthyroidism did not have a significant impact on mortality. The most common forms of thyroid dysfunction were subclinical hypothyroidism (n = 41, 9%), followed by subclinical hyperthyroidism (n = 35, 7%), low-T3 syndrome (n = 17, 4%), and overt hypothyroidism (n = 12, 3%).

“Monitoring thyroid function is necessary for patients with IDCM, and further study is warranted to investigate whether reversing low thyroid function can benefit these patients,” the investigators noted.

Read the full article here: (J. Clin. Endocrinol. Metab. 2015 [doi:10.1210/jc.2014-4159]).

The investigators reported that they had no financial disclosures to make.

Thyroid dysfunction was associated with an increased risk of mortality in patients with heart failure due to idiopathic dilated cardiomyopathy (IDCM), according to research reported in the Journal of Clinical Endocrinology and Metabolism.

Lead author Wenyao Wang of the Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, and associates gathered data from 458 consecutive patients with IDCM who were admitted to the National Center of Cardiovascular diseases in Beijing, and then evaluated their risk of mortality based on levels of free T₃ and TSH and the whole thyroid function profile.

Hypothyroidism was the strongest predictor of mortality (hazard ratio, 4.189; 95% confidence interval, 2.118-8.283), followed by low-T₃ syndrome (HR, 3.147; 95% CI, 1.558-6.355) and subclinical hypothyroidism (HR, 2.869; 95% CI, 1.817-4.532); subclinical hyperthyroidism did not have a significant impact on mortality. The most common forms of thyroid dysfunction were subclinical hypothyroidism (n = 41, 9%), followed by subclinical hyperthyroidism (n = 35, 7%), low-T3 syndrome (n = 17, 4%), and overt hypothyroidism (n = 12, 3%).

“Monitoring thyroid function is necessary for patients with IDCM, and further study is warranted to investigate whether reversing low thyroid function can benefit these patients,” the investigators noted.

Read the full article here: (J. Clin. Endocrinol. Metab. 2015 [doi:10.1210/jc.2014-4159]).

The investigators reported that they had no financial disclosures to make.

Thyroid dysfunction was associated with an increased risk of mortality in patients with heart failure due to idiopathic dilated cardiomyopathy (IDCM), according to research reported in the Journal of Clinical Endocrinology and Metabolism.

Lead author Wenyao Wang of the Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, and associates gathered data from 458 consecutive patients with IDCM who were admitted to the National Center of Cardiovascular diseases in Beijing, and then evaluated their risk of mortality based on levels of free T₃ and TSH and the whole thyroid function profile.

Hypothyroidism was the strongest predictor of mortality (hazard ratio, 4.189; 95% confidence interval, 2.118-8.283), followed by low-T₃ syndrome (HR, 3.147; 95% CI, 1.558-6.355) and subclinical hypothyroidism (HR, 2.869; 95% CI, 1.817-4.532); subclinical hyperthyroidism did not have a significant impact on mortality. The most common forms of thyroid dysfunction were subclinical hypothyroidism (n = 41, 9%), followed by subclinical hyperthyroidism (n = 35, 7%), low-T3 syndrome (n = 17, 4%), and overt hypothyroidism (n = 12, 3%).

“Monitoring thyroid function is necessary for patients with IDCM, and further study is warranted to investigate whether reversing low thyroid function can benefit these patients,” the investigators noted.

Read the full article here: (J. Clin. Endocrinol. Metab. 2015 [doi:10.1210/jc.2014-4159]).

The investigators reported that they had no financial disclosures to make.

Thyroid dysfunction was associated with an increased risk of mortality in patients with heart failure due to idiopathic dilated cardiomyopathy (IDCM), according to research reported in the Journal of Clinical Endocrinology and Metabolism.

Lead author Wenyao Wang of the Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, and associates gathered data from 458 consecutive patients with IDCM who were admitted to the National Center of Cardiovascular diseases in Beijing, and then evaluated their risk of mortality based on levels of free T₃ and TSH and the whole thyroid function profile.

Hypothyroidism was the strongest predictor of mortality (hazard ratio, 4.189; 95% confidence interval, 2.118-8.283), followed by low-T₃ syndrome (HR, 3.147; 95% CI, 1.558-6.355) and subclinical hypothyroidism (HR, 2.869; 95% CI, 1.817-4.532); subclinical hyperthyroidism did not have a significant impact on mortality. The most common forms of thyroid dysfunction were subclinical hypothyroidism (n = 41, 9%), followed by subclinical hyperthyroidism (n = 35, 7%), low-T3 syndrome (n = 17, 4%), and overt hypothyroidism (n = 12, 3%).

“Monitoring thyroid function is necessary for patients with IDCM, and further study is warranted to investigate whether reversing low thyroid function can benefit these patients,” the investigators noted.

Read the full article here: (J. Clin. Endocrinol. Metab. 2015 [doi:10.1210/jc.2014-4159]).

The investigators reported that they had no financial disclosures to make.

[email protected]

Thyroid dysfunction was associated with an increased risk of mortality in patients with heart failure due to idiopathic dilated cardiomyopathy (IDCM), according to research reported in the Journal of Clinical Endocrinology and Metabolism.

Lead author Wenyao Wang of the Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, and associates gathered data from 458 consecutive patients with IDCM who were admitted to the National Center of Cardiovascular diseases in Beijing, and then evaluated their risk of mortality based on levels of free T₃ and TSH and the whole thyroid function profile.

Hypothyroidism was the strongest predictor of mortality (hazard ratio, 4.189; 95% confidence interval, 2.118-8.283), followed by low-T₃ syndrome (HR, 3.147; 95% CI, 1.558-6.355) and subclinical hypothyroidism (HR, 2.869; 95% CI, 1.817-4.532); subclinical hyperthyroidism did not have a significant impact on mortality. The most common forms of thyroid dysfunction were subclinical hypothyroidism (n = 41, 9%), followed by subclinical hyperthyroidism (n = 35, 7%), low-T3 syndrome (n = 17, 4%), and overt hypothyroidism (n = 12, 3%).

“Monitoring thyroid function is necessary for patients with IDCM, and further study is warranted to investigate whether reversing low thyroid function can benefit these patients,” the investigators noted.

Read the full article here: (J. Clin. Endocrinol. Metab. 2015 [doi:10.1210/jc.2014-4159]).

The investigators reported that they had no financial disclosures to make.

[email protected]

Thyroid dysfunction was associated with an increased risk of mortality in patients with heart failure due to idiopathic dilated cardiomyopathy (IDCM), according to research reported in the Journal of Clinical Endocrinology and Metabolism.

Lead author Wenyao Wang of the Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, and associates gathered data from 458 consecutive patients with IDCM who were admitted to the National Center of Cardiovascular diseases in Beijing, and then evaluated their risk of mortality based on levels of free T₃ and TSH and the whole thyroid function profile.

Hypothyroidism was the strongest predictor of mortality (hazard ratio, 4.189; 95% confidence interval, 2.118-8.283), followed by low-T₃ syndrome (HR, 3.147; 95% CI, 1.558-6.355) and subclinical hypothyroidism (HR, 2.869; 95% CI, 1.817-4.532); subclinical hyperthyroidism did not have a significant impact on mortality. The most common forms of thyroid dysfunction were subclinical hypothyroidism (n = 41, 9%), followed by subclinical hyperthyroidism (n = 35, 7%), low-T3 syndrome (n = 17, 4%), and overt hypothyroidism (n = 12, 3%).

“Monitoring thyroid function is necessary for patients with IDCM, and further study is warranted to investigate whether reversing low thyroid function can benefit these patients,” the investigators noted.

Read the full article here: (J. Clin. Endocrinol. Metab. 2015 [doi:10.1210/jc.2014-4159]).

The investigators reported that they had no financial disclosures to make.

[email protected]

African American and Hispanic adolescents and adults under the age of 40 years were more likely to die from differentiated thyroid cancer than were non-Hispanic whites from the same age range, said the authors of a newly published study in Thyroid.

Lead author Theresa H.M. Keegan, Ph.D., of Stanford (Calif.) University and her associates used the California Cancer Registry to obtain data on 16,827 adolescents and young adults who had a diagnosis of differentiated thyroid cancer between 1988 and 2010. Older young adults aged 35-39 years (versus 15- to 29-year-olds), men (hazard ratio, 2.77; 95% confidence interval, 1.62-4.72), and adolescents and young adults of African American or Hispanic race/ethnicity (versus non-Hispanic whites) had worse thyroid cancer–specific survival than did non-Hispanic whites, judging from findings of multivariate analyses using Cox proportional hazards regression.

In addition, residence in low-socioeconomic-status neighborhoods (HR, 3.11; 95% CI, 1.28-7.56) and nonmetropolitan areas (HR, 5.53; 95% CI, 2.07-14.78) was associated with worse thyroid cancer–specific survival among adolescent and young adult men but not adolescent and young adult women.

“Our study is one of the first to simultaneously consider the impact of small-area neighborhood [socioeconomic status], health insurance, marital status, diagnosis of subsequent cancers, and a number of tumor characteristics on survival after” differentiated thyroid cancer in adolescents and young adults, the authors noted.

Read the full article here (Thyroid 2015;25:635-48 [doi:10.1089/thy.2015.0021]).

The authors reported that they did not have any competing financial interests.

[email protected]

African American and Hispanic adolescents and adults under the age of 40 years were more likely to die from differentiated thyroid cancer than were non-Hispanic whites from the same age range, said the authors of a newly published study in Thyroid.

Lead author Theresa H.M. Keegan, Ph.D., of Stanford (Calif.) University and her associates used the California Cancer Registry to obtain data on 16,827 adolescents and young adults who had a diagnosis of differentiated thyroid cancer between 1988 and 2010. Older young adults aged 35-39 years (versus 15- to 29-year-olds), men (hazard ratio, 2.77; 95% confidence interval, 1.62-4.72), and adolescents and young adults of African American or Hispanic race/ethnicity (versus non-Hispanic whites) had worse thyroid cancer–specific survival than did non-Hispanic whites, judging from findings of multivariate analyses using Cox proportional hazards regression.

In addition, residence in low-socioeconomic-status neighborhoods (HR, 3.11; 95% CI, 1.28-7.56) and nonmetropolitan areas (HR, 5.53; 95% CI, 2.07-14.78) was associated with worse thyroid cancer–specific survival among adolescent and young adult men but not adolescent and young adult women.

“Our study is one of the first to simultaneously consider the impact of small-area neighborhood [socioeconomic status], health insurance, marital status, diagnosis of subsequent cancers, and a number of tumor characteristics on survival after” differentiated thyroid cancer in adolescents and young adults, the authors noted.

Read the full article here (Thyroid 2015;25:635-48 [doi:10.1089/thy.2015.0021]).

The authors reported that they did not have any competing financial interests.

[email protected]

African American and Hispanic adolescents and adults under the age of 40 years were more likely to die from differentiated thyroid cancer than were non-Hispanic whites from the same age range, said the authors of a newly published study in Thyroid.

Lead author Theresa H.M. Keegan, Ph.D., of Stanford (Calif.) University and her associates used the California Cancer Registry to obtain data on 16,827 adolescents and young adults who had a diagnosis of differentiated thyroid cancer between 1988 and 2010. Older young adults aged 35-39 years (versus 15- to 29-year-olds), men (hazard ratio, 2.77; 95% confidence interval, 1.62-4.72), and adolescents and young adults of African American or Hispanic race/ethnicity (versus non-Hispanic whites) had worse thyroid cancer–specific survival than did non-Hispanic whites, judging from findings of multivariate analyses using Cox proportional hazards regression.

In addition, residence in low-socioeconomic-status neighborhoods (HR, 3.11; 95% CI, 1.28-7.56) and nonmetropolitan areas (HR, 5.53; 95% CI, 2.07-14.78) was associated with worse thyroid cancer–specific survival among adolescent and young adult men but not adolescent and young adult women.

“Our study is one of the first to simultaneously consider the impact of small-area neighborhood [socioeconomic status], health insurance, marital status, diagnosis of subsequent cancers, and a number of tumor characteristics on survival after” differentiated thyroid cancer in adolescents and young adults, the authors noted.

Read the full article here (Thyroid 2015;25:635-48 [doi:10.1089/thy.2015.0021]).

The authors reported that they did not have any competing financial interests.

[email protected]

The Food and Drug Administration has launched an online resource with a centralized, easily-navigable layout for approved Risk Evaluation and Mitigation Strategies (REMS), required by the FDA to help ensure that health care providers have information on risks and treatment strategies associated with certain drugs.

The database will have information about currently approved individual and shared system REMS – as well as historical and released REMS – providing health care providers and the general public with necessary information for managing a known or potential serious risk associated with a drug.

A provision of the Food and Drug Administration Amendments Act, enacted in 2007, gave the FDA the authority to require a REMS from manufacturers if the drug has potential risks associated with its use.

To access the database, go to this FDA website.

[email protected]

The Food and Drug Administration has launched an online resource with a centralized, easily-navigable layout for approved Risk Evaluation and Mitigation Strategies (REMS), required by the FDA to help ensure that health care providers have information on risks and treatment strategies associated with certain drugs.

The database will have information about currently approved individual and shared system REMS – as well as historical and released REMS – providing health care providers and the general public with necessary information for managing a known or potential serious risk associated with a drug.

A provision of the Food and Drug Administration Amendments Act, enacted in 2007, gave the FDA the authority to require a REMS from manufacturers if the drug has potential risks associated with its use.

To access the database, go to this FDA website.

[email protected]

The Food and Drug Administration has launched an online resource with a centralized, easily-navigable layout for approved Risk Evaluation and Mitigation Strategies (REMS), required by the FDA to help ensure that health care providers have information on risks and treatment strategies associated with certain drugs.

The database will have information about currently approved individual and shared system REMS – as well as historical and released REMS – providing health care providers and the general public with necessary information for managing a known or potential serious risk associated with a drug.

A provision of the Food and Drug Administration Amendments Act, enacted in 2007, gave the FDA the authority to require a REMS from manufacturers if the drug has potential risks associated with its use.

To access the database, go to this FDA website.

[email protected]

The Food and Drug Administration has approved Promacta for the treatment of chronic immune thrombocytopenia in children 6 years and older, Novartis, the drug’s manufacturer, announced in a statement.

Promacta (eltrombopag) is an oral thrombopoietin receptor agonist that increases platelet production by inducing stimulation and differentiation of megakaryocytes from bone marrow stem cells. Chronic immune thrombocytopenia (ITP) patients often have low platelet counts and are at risk for significant bleeding.

Promacta was approved for adult use in 2008; the drug was evaluated for pediatric use in PETIT and PETIT2, two multiphase, double-blind placebo-controlled trials designed to evaluate the drug’s safety profile. Both studies found Promacta’s safety to be consistent with the known safety profile of Promacta in chronic ITP in adults.

Promacta’s manufacturers say the drug can be useful for chronic ITP patients who have had an insufficient response to the most commonly available and used therapies for chronic ITP, such as corticosteroids, intravenous immunoglobulin, or splenectomy. ITP affects as many as 5 in 100,000 children each year.

The most common adverse reactions to Promacta in pediatric chronic ITP patients were upper respiratory tract infection, nasopharyngitis, and rhinitis. In adults, Promacta has been associated with nausea, diarrhea, upper respiratory tract infection, and vomiting; rarer but more serious side effects include liver problems, high platelet counts, a higher risk for blood clots, and new or worsened cataracts.

[email protected]

The Food and Drug Administration has approved Promacta for the treatment of chronic immune thrombocytopenia in children 6 years and older, Novartis, the drug’s manufacturer, announced in a statement.

Promacta (eltrombopag) is an oral thrombopoietin receptor agonist that increases platelet production by inducing stimulation and differentiation of megakaryocytes from bone marrow stem cells. Chronic immune thrombocytopenia (ITP) patients often have low platelet counts and are at risk for significant bleeding.

Promacta was approved for adult use in 2008; the drug was evaluated for pediatric use in PETIT and PETIT2, two multiphase, double-blind placebo-controlled trials designed to evaluate the drug’s safety profile. Both studies found Promacta’s safety to be consistent with the known safety profile of Promacta in chronic ITP in adults.

Promacta’s manufacturers say the drug can be useful for chronic ITP patients who have had an insufficient response to the most commonly available and used therapies for chronic ITP, such as corticosteroids, intravenous immunoglobulin, or splenectomy. ITP affects as many as 5 in 100,000 children each year.

The most common adverse reactions to Promacta in pediatric chronic ITP patients were upper respiratory tract infection, nasopharyngitis, and rhinitis. In adults, Promacta has been associated with nausea, diarrhea, upper respiratory tract infection, and vomiting; rarer but more serious side effects include liver problems, high platelet counts, a higher risk for blood clots, and new or worsened cataracts.

[email protected]

The Food and Drug Administration has approved Promacta for the treatment of chronic immune thrombocytopenia in children 6 years and older, Novartis, the drug’s manufacturer, announced in a statement.

Promacta (eltrombopag) is an oral thrombopoietin receptor agonist that increases platelet production by inducing stimulation and differentiation of megakaryocytes from bone marrow stem cells. Chronic immune thrombocytopenia (ITP) patients often have low platelet counts and are at risk for significant bleeding.

Promacta was approved for adult use in 2008; the drug was evaluated for pediatric use in PETIT and PETIT2, two multiphase, double-blind placebo-controlled trials designed to evaluate the drug’s safety profile. Both studies found Promacta’s safety to be consistent with the known safety profile of Promacta in chronic ITP in adults.

Promacta’s manufacturers say the drug can be useful for chronic ITP patients who have had an insufficient response to the most commonly available and used therapies for chronic ITP, such as corticosteroids, intravenous immunoglobulin, or splenectomy. ITP affects as many as 5 in 100,000 children each year.

The most common adverse reactions to Promacta in pediatric chronic ITP patients were upper respiratory tract infection, nasopharyngitis, and rhinitis. In adults, Promacta has been associated with nausea, diarrhea, upper respiratory tract infection, and vomiting; rarer but more serious side effects include liver problems, high platelet counts, a higher risk for blood clots, and new or worsened cataracts.

[email protected]

Though atopic dermatitis is often regarded as infrequent in adulthood, only 40% of study subjects with current eczema reported onset of the disease in childhood, with most beginning after adulthood, according to data published in the Journal of the European Academy of Dermatology and Venereology.

In a national multicenter, population-based study, Dr. Giancarlo Pesce of the University of Verona (Italy) and his associates administered the GEIRD (Gene-Environment Interactions in Respiratory Diseases) screening questionnaire to 10,464 randomly selected adults aged 20-44 years and gathered data on the frequency and prevalence of doctor-diagnosed eczema, asthma, and hay fever, as well as sociodemographic characteristics and environmental determinants such as smoking habits, traffic, and local pollution levels.

The prevalence of current eczema was 8.1%; the prevalence of eczema with asthma and/or hay fever (EAH), which was adopted as a proxy of atopic dermatitis, was 3.4%. About 60% of the subjects with current eczema reported onset of the disease in adulthood. After adjusting for confounders, the risk of having eczema and EAH was 57% higher in women than in men, and the risk for EAH was 86% higher in women than in men.

Read the full article here: J. Eur. Acad. Dermatol. Venereol. 2015;29:1180-7 (doi: 10.1111/jdv.12784).

Though atopic dermatitis is often regarded as infrequent in adulthood, only 40% of study subjects with current eczema reported onset of the disease in childhood, with most beginning after adulthood, according to data published in the Journal of the European Academy of Dermatology and Venereology.

In a national multicenter, population-based study, Dr. Giancarlo Pesce of the University of Verona (Italy) and his associates administered the GEIRD (Gene-Environment Interactions in Respiratory Diseases) screening questionnaire to 10,464 randomly selected adults aged 20-44 years and gathered data on the frequency and prevalence of doctor-diagnosed eczema, asthma, and hay fever, as well as sociodemographic characteristics and environmental determinants such as smoking habits, traffic, and local pollution levels.

The prevalence of current eczema was 8.1%; the prevalence of eczema with asthma and/or hay fever (EAH), which was adopted as a proxy of atopic dermatitis, was 3.4%. About 60% of the subjects with current eczema reported onset of the disease in adulthood. After adjusting for confounders, the risk of having eczema and EAH was 57% higher in women than in men, and the risk for EAH was 86% higher in women than in men.

Read the full article here: J. Eur. Acad. Dermatol. Venereol. 2015;29:1180-7 (doi: 10.1111/jdv.12784).

Though atopic dermatitis is often regarded as infrequent in adulthood, only 40% of study subjects with current eczema reported onset of the disease in childhood, with most beginning after adulthood, according to data published in the Journal of the European Academy of Dermatology and Venereology.

In a national multicenter, population-based study, Dr. Giancarlo Pesce of the University of Verona (Italy) and his associates administered the GEIRD (Gene-Environment Interactions in Respiratory Diseases) screening questionnaire to 10,464 randomly selected adults aged 20-44 years and gathered data on the frequency and prevalence of doctor-diagnosed eczema, asthma, and hay fever, as well as sociodemographic characteristics and environmental determinants such as smoking habits, traffic, and local pollution levels.

The prevalence of current eczema was 8.1%; the prevalence of eczema with asthma and/or hay fever (EAH), which was adopted as a proxy of atopic dermatitis, was 3.4%. About 60% of the subjects with current eczema reported onset of the disease in adulthood. After adjusting for confounders, the risk of having eczema and EAH was 57% higher in women than in men, and the risk for EAH was 86% higher in women than in men.

Read the full article here: J. Eur. Acad. Dermatol. Venereol. 2015;29:1180-7 (doi: 10.1111/jdv.12784).

Though atopic dermatitis is often regarded as infrequent in adulthood, only 40% of study subjects with current eczema reported onset of the disease in childhood, with most beginning after adulthood, according to data published in the Journal of the European Academy of Dermatology and Venereology.

In a national multicenter, population-based study, Dr. Giancarlo Pesce of the University of Verona (Italy) and his associates administered the GEIRD (Gene-Environment Interactions in Respiratory Diseases) screening questionnaire to 10,464 randomly selected adults aged 20-44 years and gathered data on the frequency and prevalence of doctor-diagnosed eczema, asthma, and hay fever, as well as sociodemographic characteristics and environmental determinants such as smoking habits, traffic, and local pollution levels.

The prevalence of current eczema was 8.1%; the prevalence of eczema with asthma and/or hay fever (EAH), which was adopted as a proxy of atopic dermatitis, was 3.4%. About 60% of the subjects with current eczema reported onset of the disease in adulthood. After adjusting for confounders, the risk of having eczema and EAH was 57% higher in women than in men, and the risk for EAH was 86% higher in women than in men.

Read the full article here: J. Eur. Acad. Dermatol. Venereol. 2015;29:1180-7 (doi: 10.1111/jdv.12784).

[email protected]

Though atopic dermatitis is often regarded as infrequent in adulthood, only 40% of study subjects with current eczema reported onset of the disease in childhood, with most beginning after adulthood, according to data published in the Journal of the European Academy of Dermatology and Venereology.

In a national multicenter, population-based study, Dr. Giancarlo Pesce of the University of Verona (Italy) and his associates administered the GEIRD (Gene-Environment Interactions in Respiratory Diseases) screening questionnaire to 10,464 randomly selected adults aged 20-44 years and gathered data on the frequency and prevalence of doctor-diagnosed eczema, asthma, and hay fever, as well as sociodemographic characteristics and environmental determinants such as smoking habits, traffic, and local pollution levels.

The prevalence of current eczema was 8.1%; the prevalence of eczema with asthma and/or hay fever (EAH), which was adopted as a proxy of atopic dermatitis, was 3.4%. About 60% of the subjects with current eczema reported onset of the disease in adulthood. After adjusting for confounders, the risk of having eczema and EAH was 57% higher in women than in men, and the risk for EAH was 86% higher in women than in men.

Read the full article here: J. Eur. Acad. Dermatol. Venereol. 2015;29:1180-7 (doi: 10.1111/jdv.12784).

[email protected]

Though atopic dermatitis is often regarded as infrequent in adulthood, only 40% of study subjects with current eczema reported onset of the disease in childhood, with most beginning after adulthood, according to data published in the Journal of the European Academy of Dermatology and Venereology.

In a national multicenter, population-based study, Dr. Giancarlo Pesce of the University of Verona (Italy) and his associates administered the GEIRD (Gene-Environment Interactions in Respiratory Diseases) screening questionnaire to 10,464 randomly selected adults aged 20-44 years and gathered data on the frequency and prevalence of doctor-diagnosed eczema, asthma, and hay fever, as well as sociodemographic characteristics and environmental determinants such as smoking habits, traffic, and local pollution levels.

The prevalence of current eczema was 8.1%; the prevalence of eczema with asthma and/or hay fever (EAH), which was adopted as a proxy of atopic dermatitis, was 3.4%. About 60% of the subjects with current eczema reported onset of the disease in adulthood. After adjusting for confounders, the risk of having eczema and EAH was 57% higher in women than in men, and the risk for EAH was 86% higher in women than in men.

Read the full article here: J. Eur. Acad. Dermatol. Venereol. 2015;29:1180-7 (doi: 10.1111/jdv.12784).

[email protected]